Clinical trial · Interventional
Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Diagnostic Ureteroscopy for Primary Upper Tract Urothelial Carcinoma Patients
Peking University First Hospital
NCT02740426CI-TRIAL-00029626unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical trial is designed to evaluate the efficacy of single immediate intravesical chemotherapy instillation in the prevention of bladder recurrence after diagnostic ureteroscopy for upper tract urothelial carcinoma (UTUC) patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Recurrence | — | UNRESOLVED | — |
| Upper Tract Urothelial Carcinoma | Renal Pelvis and Ureter Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pirarubicin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- Blank control
- description
- do not use prophylactic intravesical chemotherapy.
- type
- EXPERIMENTAL
- label
- Single intravesical instillation
- description
- intravesical instillation within 24 hours postoperatively
- interventionNames
- Drug: Pirarubicin
Primary outcomes (1)
- measure
- intravesical recurrence-free survival
- timeFrame
- three years after surgery
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Suspected UTUC patients without history of bladder tumor. * Suspected UTUC patients without synchronous bladder tumor. * Suspected UTUC patients without contralateral UTUCs. Exclusion Criteria: * Patients with history of bladder tumor. * Patients with synchronous bladder tumor. * Patients with contralateral UTUCs. * Patients with advanced stage (T4). * Patients with other malignant tumors.
References
Publications (0)
Data not yet available
No reference posted for this study.